Robert M. Sharkey

16.4k total citations · 2 hit papers
281 papers, 12.1k citations indexed

About

Robert M. Sharkey is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Robert M. Sharkey has authored 281 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 245 papers in Radiology, Nuclear Medicine and Imaging, 114 papers in Oncology and 52 papers in Molecular Biology. Recurrent topics in Robert M. Sharkey's work include Radiopharmaceutical Chemistry and Applications (202 papers), Monoclonal and Polyclonal Antibodies Research (173 papers) and HER2/EGFR in Cancer Research (60 papers). Robert M. Sharkey is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (202 papers), Monoclonal and Polyclonal Antibodies Research (173 papers) and HER2/EGFR in Cancer Research (60 papers). Robert M. Sharkey collaborates with scholars based in United States, Netherlands and France. Robert M. Sharkey's co-authors include David M. Goldenberg, William J. McBride, Edmund A. Rossi, Chien‐Hsing Chang, Thomas M. Cardillo, Serengulam V. Govindan, Habibe Karacay, F. James Primus, Rosalyn D. Blumenthal and Otto C. Boerman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Robert M. Sharkey

280 papers receiving 11.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

2019 599 citations Aditya Bardia, Linda T. Vahdat et al. profile →
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

2015 349 citations David M. Goldenberg, Thomas M. Cardillo et al. Oncotarget profile →

Peers

Countries citing papers authored by Robert M. Sharkey

Since Specialization

Citations

This map shows the geographic impact of Robert M. Sharkey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Sharkey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Sharkey more than expected).

Fields of papers citing papers by Robert M. Sharkey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Sharkey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Sharkey. The network helps show where Robert M. Sharkey may publish in the future.

Co-authorship network of co-authors of Robert M. Sharkey

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Sharkey. A scholar is included among the top collaborators of Robert M. Sharkey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Sharkey. Robert M. Sharkey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas 2024 ·Oncotarget ·Thomas M. Cardillo, (unknown), Roberto Arrojo, Robert M. Sharkey, Serengulam V. Govindan, Chien‐Hsing Chang, David M. Goldenberg	9
2	Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer 2020 ·Journal of Nuclear Medicine ·Caroline Rousseau, David M. Goldenberg, (unknown), (unknown), (unknown), Ludovic Ferrer, (unknown), (unknown), Damien Masson, Mario Campone, A. Rauscher, Vincent Fleury, Catherine Labbé, (unknown), (unknown), Claire Toquet, Jacques Barbet, Robert M. Sharkey, L. Campion, Françoise Kraeber‐Bodéré	28
3	Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial 2020 ·Annals of Oncology ·Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy, R Moroose, IA Mayer, Vandana G. Abramson, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, Trishna Goswami, William A. Wegener, Aditya Bardia	111
4	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy 2020 ·Expert Opinion on Biological Therapy ·David M. Goldenberg, Robert M. Sharkey	81
5	Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan 2017 ·Journal of Clinical Oncology ·Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, W. Thomas Purcell, Alexander Starodub, Leora Horn, Ronald Scheff, Aditya Bardia, Wells A. Messersmith, Jordan Berlin, Allyson J. Ocean, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg, D. Ross Camidge	139
6	Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130) 2017 ·Molecular Cancer Therapeutics ·Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, (unknown), Jing Xia, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg	24
7	Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –wild-type Triple-Negative Breast Cancer 2017 ·Clinical Cancer Research ·Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, (unknown), David M. Goldenberg	98
8	Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan) 2015 ·Clinical Cancer Research ·Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg	130
9	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors 2015 ·Clinical Cancer Research ·Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Linda T. Vahdat, Sajeve Thomas, Serengulam V. Govindan, Pius Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg	252
10	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma 2014 ·Haematologica ·Thomas E. Witzig, Michael Tomblyn, Jamal Misleh, Ebenezer A. Kio, Robert M. Sharkey, (unknown), David M. Goldenberg	19
11	Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers 2013 ·Molecular Cancer Therapeutics ·Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold, David M. Goldenberg	107
12	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement 2012 ·Journal of Nuclear Medicine ·Pierre‐Yves Salaün, L. Campion, Claire Bournaud, Alain Faivre-Chauvet, Jean‐Philippe Vuillez, David Taïeb, C. Ansquer, Caroline Rousseau, Françoise Borson‐Chazot, Stéphane Bardet, A. Oudoux, Bertrand Cariou, Éric Mirallié, Chien‐Hsing Chang, Robert M. Sharkey, David M. Goldenberg, Jean‐François Chatal, Jacques Barbet, Françoise Kraeber‐Bodéré	44
13	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer 2012 ·Journal of Nuclear Medicine ·Rafke Schoffelen, Winette T.A. van der Graaf, Robert M. Sharkey, Gerben M. Franssen, William J. McBride, Chien‐Hsing Chang, Desirée L. Bos, David M. Goldenberg, Wim J.G. Oyen, Otto C. Boerman	11
14	Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies 2011 ·Molecular Cancer Therapeutics ·Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, David M. Goldenberg	50
15	Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models 2011 ·Molecular Cancer Therapeutics ·Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan, David M. Goldenberg	40
16	Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys 2011 ·Clinical Cancer Research ·Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, David M. Goldenberg	217
17	Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies 2010 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert M. Sharkey, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg	16
18	Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non–Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody 2008 ·Cancer Research ·Robert M. Sharkey, Habibe Karacay, Samuel Litwin, Edmund A. Rossi, William J. McBride, Chien‐Hsing Chang, David M. Goldenberg	60
19	A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma 2008 ·Cancer Research ·David V. Gold, David M. Goldenberg, Habibe Karacay, Edmund A. Rossi, Chien‐Hsing Chang, Thomas M. Cardillo, William J. McBride, Robert M. Sharkey	53
20	Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. 1990 ·PubMed ·(unknown), Robert M. Sharkey, David M. Goldenberg	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact